Figure 1. Changes in body weight (A), and serum glucose (B), TG (C), TC (D), insulin (E) and HbA1c (F) levels in SDT fatty rats with canagliflozin (SGLT2-I)-treatment. Data are represented as means ± standard deviation or + standard deviation (n=4-6). *p<0.05, ** p<0.01; significant difference compared with the control group. #p<0.05, ## p<0.01; significant difference compared to the SD group.
